I3 customers will be given expertise in over seeing clinical trials licenses, etc. and assistance getting through regulatory processes, like the FDA.  ChinaGate is located in Shanghai, China image. United has been very outspoken on keeping cost down so this appears to be an acquisition not only for facilitating clinical trials but also as an arm to oversee getting products, drugs and medical devices through the US FDA and the European CE market requirements. 

From the website:

“We are familiar with the Chinese regulatory system and are well connected with most of the top urban class A  hospitals and clinical trial centers that are GCP certified by the China State Food and Drug Administration (SFDA). Moreover, since we worked many years in multi-national pharmaceutical companies ,we are well versed in ICH, European and United States Food and Drug Administration (FDA) requirements on Good Clinical Practice (GCP).

This appears to be a vested interest in potentially bringing lower cost drugs and medical devices to the US and other countries.  BD  

A subsidiary of UnitedHealth Group Inc. has acquired ChinaGate, a firm that helps drug, device and biotech companies enter the Chinese market, the companies said Wednesday.

I3, a company owned by Minnetonka-based UnitedHealth's technology arm, Ingenix, bought Shanghai-based ChinaGate for an undisclosed sum.

The companies said ChinaGate has extensive experience with the State Food and Drug Administration, China's version of the U.S. Food and Drug Administration, and has helped bring more than 450 medical and consumer health products into the Chinese market.

UnitedHealth subsidiary buys Chinese gateway company | StarTribune.com


Post a Comment

Google Analytics Alternative